NOV120401 (CKD-516 Tablet) for Advanced Solid Tumors

Summary

The purpose of this open-label, dose-escalation phase I trial is to evaluate the safety, tolerability and pharmacokinetic profiles and to assess the efficacy of NOV120401 (CKD-516 Tablet), a novel vascular disrupting agent, in patients with advanced refractory solid tumors.

Timeline

Start

2014-12

Primary completion

2016-07

Completion

2016-07

Drugs

Indications